As early as 1914 Schwarz (1) suspected an inverse relationship between adrenal activity and the level of circulating eosinophils. Twenty-five years later Dalton and Selye (2) noted eosinopenia following stress in animals and related it to release of adrenal cortical hormones. More recently Thorn and his associates (3, 4) observed a prompt decrease in circulating eosinophils in healthy persons, and in patients, following a single injection of pituitary adrenocorticotropic hormone (A.C.-T.H. or corticotropin). The greatest reduction in eosinophils was seen four hours after injection and was related to secretary activity of the adrenal cortex. In a study of 40 people with normal adrenal activity Thorn, Forsham, Prunty, and Hills (5) reported that the mean drop in circulating eosinophils at four hours was 70%o below preinjection levels. In all instances the drop in circulating eosinophils was greater than 45%o. This was in sharp contrast to what was seen in patients with Addison's disease, where they noted little change in circulating eosinophils after injection of corticotropin. Thorn, therefore, proposed that the eosinophil response to A.C.T.H. should be used as a test in the diagnosis of Addison's disease. He and Forsham suggested (6) that a fourhour post-injection ". . . fall of 50%o or more of the circulating eosinophils eliminates the diagnosis of adrenal cortical insufficiency," and they indicated that an inadequate response, of less than 50%o fall, may represent true adrenal cortical insufficiency.
A transitory eosinopenia also develops in animals after injection of epinephrine. On the basis of extirpation and electrical stimulation studies on dogs by Hume and Wittenstein (7, 8) , Recant, Hume, Forsham, and Thorn (9) postulate that the hypothalamus, pituitary, and adrenal cortex are successively stimulated to produce epinephrine eosinopenia. They advocate a four-hour eosinophil response test to parenteral epinephrine for estimating the functional activity of the pituitaryadrenal axis in man.
In this laboratory, working with Samter, we found that oral ephedrine is also capable of producing transient eosinopenia in man (10) (11) (12) (13) . This phenomenon has been observed independently by Abelson and Moyes (14) . While the fourhour response of eosinophils to epinephrine or ephedrine has been used mainly in testing individual patients, it has also been used to measure pituitary-adrenal activity in various physiological states, such as infancy (15) , old age (16) , following operations (17) , and to assess groups of people ill with different types of disease processes such as chronic alcoholism (18) and acute gout (19) .
In order to test the validity of the different eosinophil response tests as clinical tools in diagnosis and as indices of activity of the hypothalamus, pituitary, or adrenal cortex, observations were made on a large number of patients; among whom were many with conditions thought to be related to abnormalities of the pituitary-adrenal axis. Technique of eosinophil counts. Chamber eosinophil counts were made using the phloxine-propylene glycol stain of Randolph (20) or as modified by Henneman, Wexler, and Westenhaver (21) . Four standard 0.9 mm.' Levy chambers (two hemocytometers) were filled from a single pipette after a 1: 10 dilution. The total number of cells counted in the entire ruled area of the four chambers was multiplied by 2.78 to give the number of eosinophils per mm.' of blood. 4 Corticotropin was obtained through the courtesy of: Armour and Company, Chicago (25 mg From the point of view of the present study, it was necessary to investigate the intrinsic error of chamber eosinophil counts in more detail than had been done previously so that valid statistical conclusions could be made on eosinophil counts obtained in the tests. Therefore, the standard deviation of a group of four individual chamber eosinophil counts was calculated for each of 500 blood specimens from this series. The first 400 were taken consecutively; the last 100 included only counts greater than 275 cells per mm.' as there were already sufficient observations regarding the lower mean counts. These standard deviations are plotted against the respective means of the four chamber counts as illustrated in Figure 1 .
These values are compared with the curve of maximum possible standard deviation. This curve was plotted by inspection of all possible combinations of counts in four chambers which can yield representative mean eosinophil counts. The fewer the number of chambers in such a computation, the more markedly will this limiting factor restrict the correspondence of observed values as compared to the theoretical dispersion if an unlimited number of chambers were used. Inspection of this curve shows that maximal standard deviations were reached only when the mean eosinophil counts ranged from zero to 15 cells per mm.".
The observed standard deviations were also compared with a theoretical curve for one standard deviation of counts which was derived from the formulae of Berkson, Magath, and Hurn (24) . By inspection of the data it can be seen that the observations are not equally distributed above and below the theoretical curve, the observed standard deviations being generally less than predicted, 5Berkson, Magath, and Hum (24) have pointed out the unconscious tendency towards faulty chamber counting by technicians and physicians. In their own studies they had to photograph each ruled area of the counting chamber and had to punch a hole through the photographic image of each cell to ensure absolute accuracy in cell counts made for statistical analyses.
INTRINSIC ERROR OF CHAMBER EOSINOPHIL COUNT
In addition to the universal difficulty of counting objects as seen through the microscope, there are five situations encountered in the eosinophil counting chamber where "judgment" may be substituted for complete oh- The standard deviation of repeated tests in these same subjects was also studied with relation to grouped mean levels of response (Figure 3. ). This figure shows that the greater the tendency towards eosinopenic response to this test, the more consistent are the repeated tests. Figure 4 shows Although insufficient data of this type were collected for similar statistical analysis of repeated tests of subjects to epinephrine, corticotropin, and placebos, we have noted that these tests are also not accurately reproducible, and their degree of variability appears to be correlated with the same factors.
Comparative response to corticotropin, ephedrine, and placebos The mean response to a given stimulus by each subject was analyzed with that of all other subjects so tested (excluding tests on patients with Addison's disease). Figure 5 shows the mean, the fiducial limits of the mean, the standard deviation, and the 95%o confidence limits for all fourhour observations of the percent change in eosinophils from pre-treatment levels. These are grouped for tests with placebo, with ephedrine, and with corticotropin. The much as the one standard deviation limits of all three groups overlap considerably. These limits encompass approximately two-thirds of observations for each group. Almost one-sixth of subjects given placebos showed four-hour eosinopenia of 50%o or greater and in approximately one-sixth of non-Addisonian individuals the eosinophil levels fell less than 40%o four hours after injection of corticotropin.
The mean levels of the three groups of tests and the standard deviations for each stimulus were analyzed in relation to the initial eosinophil level. The degree of response to placebo and cortico- tropin was little influenced by the mean eosinophil level, though there was a suggestion of decreasing response with high levels in tests using ephedrine ( Figure 6 ). In all instances the standard deviations for each stimulus were greater with low than with higher counts.
Examples of variable responses in individual patients Examples of the variability of the responses to the different tests are given below: The eosinophil level of a patient with refractory anemia fell 69%, 51%o, 56%o, and 35% and increased 7%o after repeated tests to placebos; they fell 45%o, 49%o, and 34%b after ephedrine testing; and they dropped 53%o after injection of corticotropin. The eosinophil level of a young diabetic patient fell only 227% after corticotropin injection, but after ephedrine the eosinophil levels fell by 76%o, 509%o, 53%, and 64%o on different occasions. Two patients with hypothyroidism were tested before and during thyroid therapy. The first of these had a 26%o
and a 29%b fall with ephedrine before therapy, a 50%o decrease the second week, and a 26% drop the third week of thyroid therapy. The second patient had a 21%o decrease and a 10%o rise before therapy, a 52%o fall one week after thyroid extract had been started, and 26%o and 11%o decrease two weeks later.
Numerous other examples of wide variation in response to repeated tests with the same agent and seemingly paradoxical responses in comparison with tests to more than one agent could be cited.
Failure of response to corticotropin
Twenty-three subjects of the 76 tested with corticotropin at first failed to show a decrease of eosinophils exceeding 50%o. Two of these had proven Addison's disease. In the first patient the eosinophils dropped 5%o, 2%o, and 23%o in three separate tests with corticotropin and increased 3%o and 8%o after ephedrine. In the second patient there was a 4%o and an 11 o rise after corticotropin, a 12%o fall after ephedrine and an 8%o drop after injection of epinephrine.
One patient, ill with dermatomyositis had been tested during the time he was receiving cortisone and presumably he did not respond because of a temporary adrenocortical insufficiency. Five patients were tested with what turned out to be an inferior batch of corticotropin. Data from these six patients were not included in the statistical analyses. It is possible that some of the other failures were partially due to preparations of substandard potency as discussed later.
The subjects in whom initial response to corticotropin was "inadequate" had a greater than 50o% eosinopenia after repeat testing with corticotropin and/or ephedrine. Unfortunately, circumstances beyond our control interfered with retesting five such patients. There was no clinical evidence, nor biochemical data to suggest adrenocortical insufficiency in any of these subjects, and it seems likely that a greater than 50%o eosinopenia would have been noted in each of them with retesting.
Response to ephedrine in pituitary disease
It is well known that up to three quarters of the pituitary gland may be destroyed with few or no symptoms of hypopituitarism (25) . These studies amply demonstrate the lack of precision inherent in the four-hour eosinophil response tests. The errors of single eosinophil counts are basic to a consideration of variation in such tests. Some of the human errors of enumeration have been mentioned in footnote number 5 of this paper. In addition there is a chance variation related to the total number of cells counted. This theoretical error has been discussed previously (11) and is represented in Figure 1 and Table I for a single pipette and both sides of two standard hemocytometers. Exact accuracy of cell counts is hard to obtain with the best will in the world, but the common error of counting insufficient cells (using only one or two sides of a single hemocytometer) is easily avoided. We recommend at least four standard chambers (two hemocytometers), or preferably, four large Fuchs-Rosenthal chambers.
It is seen from Table I that the theoretical coefficient of variation for single specimens is greatest with low eosinophil counts. The error of comparing successive counts would be expected to reflect a similar relationship to initial eosinophil level. This was borne out in the standard deviations of Figure 2 for repeated tests in the same subject and in Figure 6 for the comparison of mean responses in many subjects. Thus, the greatest variation is noted with the lowest initial counts.
With higher initial eosinophil counts the intrinsic errors of counting became of less importance. In spite of this, a standard deviation of approximately 18%7o persists for repeated tests on subjects with high initial levels (Figure 2 ). This variability is apparently related to short term fluctuations in eosinophil level as described by Rud (26) as well as to alterations in the physiological state of the subjects. In order to minimize these factors it is important to see that the subject is under the least possible stress during the test.
As shown in Figure 3 the standard deviation of repeated tests was greater in subjects showing slight or no mean response than in those with a marked fall in eosinophils. This may be at least partially explained by the simple arithmetic fact that to yield mean values approaching a 100%o decrease of eosinophils, values for repeated tests must be more closely grouped than is necessary for cases of lesser response.
The tendency towards greater response of second over first tests, particularly when separated by more than three days, as shown in Figure 4 , may seem surprising. We feel this tendency is not significant inasmuch as early in the study repeat tests were only done on those subjects failing to show significant eosinopenia. In these patients, initial values were often lower than their mean response to subsequent repeated tests. More significant is the comparison of successive tests as related to the interval between tests. It appears that the responsiveness to ephedrine is impaired for several days after each test. We do not know whether this represents tachyphylaxis, fatigue, or adaptation. In any case, when tests are repeated they should be run at least three or more days apart.
Response to corticotropin in Addison's disease
The four-hour eosinophil response to a single injection of 25 mg. corticotropin, though a valuable tool in the diagnosis of Addison's disease, is certainly not infallible. We know of no instance in which a patient with Addison's disease has developed a significant eosinopenia to this test, but we and others (27) have observed several patients without Addison's disease who failed to respond to injection of corticotropin. Therefore, failure of response to a single test with corticotropin cannot be considered diagnostic of Addison's disease.
It must be pointed out that in the past some experimental and commercial preparations of corticotropin were poor stimulators of the adrenal gland. Most of the corticotropin used in this study was tested for potency in healthy individuals. Nevertheless variations of potency may have been responsible for a few of the subnormal responses observed after injection of corticotropin.
In the event of an inadequate response repeated tests with corticotropin are indicated. The intravenous test (28) , which gives a more powerful stimulus to the adrenal cortex than the intramuscular test, should be used in re-testing.
Epinephrine, ephedrine, and the hypothalamicpituitary-adrenal axis In the beginning of our study we used epinephrine as a stimulus for producing transitory eosinopenia. After performing over 50 tests with this agent (11) we changed to oral ephedrine which has very similar pharmacologic and physiologic effects on man; the main difference, according to Gaddum and Kwiatkowski (29) , is that ephedrine is tachyphylactic and is less readily destroyed in the body. Within the broad limits of variability for the test, ephedrine is seen to produce approximately the same degree of eosinopenia in individual subjects as do the conventionally employed doses of epinephrine.
The clinical significance of the eosinophil response tests to epinephrine and ephedrine depend on whether or not these agents induce eosinopenia through successive stimulation of the hypothalamus, pituitary, and adrenal cortex in man.
As far as we have been able to ascertain, Hume's work regarding the epinephrine effect on the hypothalamus of animals has not been repeated for either epinephrine or ephedrine (30) . In the rat the hypothalamus is not a necessary part of the axis for the production of epinephrine eosinopenia. McDermott, Fry, Brobeck, and Long (31) demonstrated that application of minute amounts of epinephrine directly to a pituitary gland transplanted into the anterior chamber of the rat's eye would induce eosinopenia, whereas parenteral injection of the same quantity was without effect.
Sayers (32) has recently suggested that ". ..epinephrine does not discharge A.C.T.H. by a direct action on the adenohypophysis or via a neural link to the gland, but rather acts to increase peripheral utilization of cortical hormones." In this regard, Robinson (33) has studied a patient with rheumatoid arthritis, made unresponsive to corticotropin by cortisone. When epinephrine was given to him there was an appreciable drop in eosinophil count. Three of our patients with Addison's disease did not show significant eosinophil responses to epinephrine while on cortisone and two responded (three of these cases were recently added to the series, and were not considered in previous discussions).
However, we have studied five patients with carcinoma of the prostate after complete adrenalectomy while they were receiving cortisone (34) . Following 0.3 mg. epinephrine, subcutaneously, eosinophils decreased by 36 to 78%o with a mean fall of 61%o. Little change in level of circulating eosinophils followed injection of saline or corticotropin.
As long as the mechanisms of epinephrine and ephedrine induced eosinopenia are not fully clarified, the interpretation of inadequate response to these agents as indicative of disturbed pituitary or adrenal function is untenable.
Is the four-hour eosinophil response test to epinephrine or ephedrine a useful clinical tool? Thorn and Forsham (6) 
